
International Journal of GASTROINTESTINAL CANCER RESEARCH

E-ISSN: 3149-997X

Volume: 1



www.gicancerjournal.com

galenos yayinevi

International Journal of
GASTROINTESTINAL CANCER RESEARCH
Volume: 1 | August **2026**

Editor-in-Chief

Prof., MD. Şuayib Yalçın
Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye
suayibyalcin@gmail.com

Executive Deputy Chief Editor

Assoc. Prof., MD. Dılşa Mızrak Kaya
TOBB University of Economics and Technology Faculty of Medicine Hospital, Department of Medical Oncology, Ankara, Türkiye
dmizrak@tobbetuhastanesi.com.tr

Editors

Prof., MD. Osman Abbasoğlu
Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye
osmanabbasoglu@yahoo.com

Assoc. Prof., MD. İrem Bilgetekin
Memorial Ankara Hospital, Clinic of Medical Oncology, Ankara, Türkiye; Üsküdar University Faculty of Medicine, Department of Internal Medicine, İstanbul, Türkiye
irembilgetekin@gmail.com

Section Editors

Upper Gastrointestinal System Cancers

Prof., MD. Leyla Özer
Memorial Bahçelievler Hospital, Clinic of Oncology; Arel University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, İstanbul, Türkiye
leyla.ozer@memorial.com.tr

Pancreatic Cancer

Prof., MD. Philip Agop Philip
Wayne State University Faculty of Medicine, Department of Oncology, Michigan, USA
ad6613@wayne.edu

Colorectal Cancer

Assoc. Prof., MD. İbrahim Halil Şahin
University of Michigan Medical School, Department of Internal Medicine, Division of Hematology and Oncology, Michigan, USA
sahinih@med.umich.edu

Neuroendocrine Tumors

Assoc. Prof., MD. Hayriye Şahinli
University of Health Sciences Türkiye, Ankara Etlik City Hospital, Department of Medical Oncology, Ankara, Türkiye
dr.hayriye@hotmail.com

Gastrointestinal Stromal and Rare Tumors

Prof., MD. Özgür Tanrıverdi
Muğla Sıtkı Koçman University Faculty of Medicine, Department of Medical Oncology, Muğla, Türkiye
dr.ozgur.tanriverdi@gmail.com

Gastrointestinal Lymphomas

Prof., MD. Serkan Akın
Hacettepe University Hospital, Department of Medical Oncology, Ankara, Türkiye
drserkanakın@gmail.com

Publisher Contact
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1 34093 İstanbul, Türkiye
Phone: +90 (530) 177 30 97 / +90 (539) 307 32 03
E-mail: info@galenos.com.tr/yayin@galenos.com.tr
Web: www.galenos.com.tr
Publisher Certificate Number: 14521

An international scientific journal with continuous publication.

Precision Oncology and Biomarkers

Prof., MD. Dan Aderka
Assuta Medical Center, Clinic of Oncology, Tel Aviv, Israel
aderkadan@gmail.com

Prof., MD. Taha Bahsi
Memorial Healthcare Group, Medroyal Genetic Disease Diagnostic Center, Department of Medical Genetics, İstanbul, Türkiye
tahabahsi@yahoo.com

Gastroenterology

Prof., MD. Hatice Yasemin Balaban
Hacettepe University Faculty of Medicine, Department of Gastroenterology, Ankara, Türkiye
ybalaban@hacettepe.edu.tr

Assoc. Prof., MD. Osman Çağın Buldukoğlu
University of Health Sciences Türkiye, Antalya Training and Research Hospital, Department of Gastroenterology, Antalya, Türkiye
cbuldukoglu@hotmail.com

Nuclear Medicine

Prof., MD. Murat Fani Bozkurt
Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Türkiye
muratfani.bozkurt@hacettepe.edu.tr

Radiology

Prof., MD. Emre Ünal
TOBB University of Economics and Technology Faculty of Medicine Hospital, Department of Radiology, Ankara, Türkiye
eunal@tobbetuhastanesi.com.tr

Cancer Genomics and Molecular Medicine

Prof., MD. Dan Aderka
Assuta Medical Center, Clinic of Oncology, Tel Aviv, Israel
aderkadan@gmail.com

Prof., MD. Taha Bahsi
Memorial Healthcare Group, Medroyal Genetic Disease Diagnostic Center, Department of Medical Genetics, İstanbul, Türkiye
tahabahsi@yahoo.com

Continuing Medical Education (CME) Editors

Assoc. Prof., MD. Ivane Kiladze
Ilia State University Faculty of Natural Sciences and Medicine, Department of Oncology, Tbilisi, Georgia
ivane6@hotmail.com

Assoc. Prof., MD. Erdoğan Selçuk Şeber
Tekirdağ Namık Kemal University Faculty of Medicine, Department of Medical Oncology, Tekirdağ, Türkiye
esseber@nku.edu.tr

Merih Yalçıner, MD
University of Health Sciences Türkiye, Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Türkiye
merihyalciner@gmail.com

Advisory Board

Prof., MD. Ola Kharsid
Cairo University, National Cancer Institute, Department of Medical Oncology, Cairo, Egypt
ola.khorshid@nci.cu.edu.eg

Prof., MD. Ulus Ali Şanlı
İzmir University of Economics MedicalPoint International Hospital, Department of Medical Oncology, İzmir, Türkiye
sanliua@gmail.com

Prof., MD. Ido Wolf
Tel Aviv Medical Center, Clinic of Oncology, Tel Aviv, Israel
idow@tlvmc.gov.il

Prof., MD. Mahmut İlhan
Memorial Diyarbakır Hospital, Clinic of Oncology, Diyarbakır, Türkiye
mahmut.ilhan@memorial.com.tr

Assoc. Prof., MD. Şahin Laçin
Koç University Hospital, Department of Medical Oncology, İstanbul, Türkiye
sahin.lacin@hotmail.com

EDITORIAL



Launching a New Era in Gastrointestinal (GI) Oncology Publishing

Dear Colleagues and Members of the Global GI Oncology Community,

It is with profound enthusiasm and a deep sense of responsibility that I welcome you to the inaugural issue of the International Journal of Gastrointestinal Cancer Research (IJGCR). This momentous launch represents not merely the establishment of another academic journal, but rather the crystallization of a collective vision-a vision shared by clinicians, researchers, and healthcare professionals worldwide who are committed to advancing the science and practice of GI oncology.

The Imperative for a Dedicated Platform

The landscape of GI cancer research has undergone a remarkable transformation over the past two decades. GI malignancies, collectively accounting for approximately one in four of all cancer cases and one in three cancer deaths globally, present an unprecedented challenge to the medical community. Yet, simultaneously, they offer unprecedented opportunities for innovation and discovery. The convergence of molecular diagnostics, precision medicine, immunotherapy, and multidisciplinary care has fundamentally altered our approach to these complex diseases.

Despite this scientific revolution, the field of GI oncology has lacked a dedicated, high-impact international journal specifically designed to serve as the primary venue for publishing cutting-edge research, clinical innovations, and translational discoveries in this domain. While excellent general oncology and specialty journals exist, they often cannot provide the focused editorial attention and specialized peer-review expertise that GI cancer research deserves. The IJGCR has been created to fill this critical gap.

Our Mission and Vision

The mission of IJGCR is to serve as the premier international platform for the dissemination of original research, clinical investigations, translational studies, and evidence-based reviews that advance our understanding and management of GI cancers. We are committed to publishing work of the highest scientific quality, rigorously peer-reviewed by experts in the field, and immediately applicable to clinical practice and future research directions.

Our vision extends beyond traditional academic publishing. IJGCR aspires to be a catalyst for international collaboration, fostering connections among researchers, clinicians, and institutions across continents. We recognize that the most significant advances in GI oncology emerge from multidisciplinary collaboration-bringing together medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, pathologists, radiologists, and basic science researchers. IJGCR will actively promote and facilitate such collaboration through our editorial policies and special initiatives.

Scope and Content

The journal will encompass the full spectrum of GI oncology, including but not limited to:

Upper GI Malignancies: Esophageal, gastric, and gastroesophageal junction cancers, with emphasis on novel therapeutic strategies, biomarker-driven approaches, and multidisciplinary management.

Colorectal Cancer: From early detection and prevention through advanced metastatic disease, including precision oncology approaches, surgical innovations, and organ-preserving strategies.

Hepatobiliary and Pancreatic Cancers: Hepatocellular carcinoma, cholangiocarcinoma, and pancreatic adenocarcinoma, with particular focus on emerging systemic therapies, regional treatment modalities, and transplantation strategies.

EDITORIAL

Rare GI Malignancies: GI stromal tumors, neuroendocrine tumors, GI lymphomas, and other uncommon entities where targeted therapy has revolutionized outcomes.

Translational Research: Molecular profiling, genomic analysis, biomarker discovery, and mechanistic studies that illuminate the biology of GI cancers and identify new therapeutic targets.

Supportive Care and Quality of Life: Palliative medicine, management of treatment-related toxicities, nutritional support, psycho-oncology, and strategies to optimize patient outcomes and quality of life.

Epidemiology and Prevention: Population-based studies, screening strategies, risk stratification, and public health approaches to reducing the burden of GI cancers globally.

Health Services Research: Health economics, healthcare delivery models, access to care, and implementation science relevant to GI oncology.

Editorial Standards and Peer-review

IJGCR is committed to the highest standards of scientific integrity and editorial excellence. All submitted manuscripts will undergo rigorous double-blind peer-review by experts in relevant subspecialties. Our editorial board comprises internationally recognized leaders in GI oncology, representing diverse geographic regions, clinical disciplines, and research expertise. This multidisciplinary composition ensures that manuscripts are evaluated not only for scientific merit but also for clinical relevance and applicability to global practice.

We adhere strictly to the principles of research ethics, including the International Committee of Medical Journal Editors guidelines. We are committed to transparency in reporting, reproducibility of findings, and the responsible communication of research results. IJGCR will maintain the highest standards of confidentiality and will not tolerate plagiarism, data fabrication, or other forms of scientific misconduct.

Global Accessibility and Impact

From its inception, IJGCR has been designed as a truly international journal. We welcome submissions from researchers and clinicians worldwide, recognizing that important advances in GI oncology emerge from institutions and healthcare systems across all continents. To ensure maximum global accessibility, IJGCR will be published in English and will be indexed in major international databases including PubMed/MEDLINE, Scopus, Web of Science, and other leading indexing services. All articles will be assigned Digital Object Identifiers to ensure permanent accessibility and accurate citation.

We are deeply committed to open science principles. IJGCR will employ an open-access model, ensuring that research findings are freely available to the global scientific community, healthcare professionals, and patients. This commitment reflects our belief that knowledge generated through scientific research should be a public good, particularly when it has the potential to improve health outcomes and save lives.

The Role of Authors, Reviewers, and Readers

The success of IJGCR will depend fundamentally on the contributions of our community. We invite researchers and clinicians to submit their best work-original investigations, clinical case reports, systematic reviews, meta-analyses, and thought-provoking commentaries that advance the field. We particularly encourage submissions from early-career researchers and from institutions in low- and middle-income countries, where GI cancer burden is often highest yet research infrastructure may be limited.

We also call upon the scientific community to serve as peer-reviewers. The peer-review process is the cornerstone of scientific publishing, and we depend upon the generosity and expertise of colleagues who volunteer their time to evaluate manuscripts. Peer-review is not merely a gatekeeping function; it is an opportunity to mentor junior researchers, to ensure scientific rigor, and to improve the quality of published work.

EDITORIAL

Finally, we invite readers to engage critically with the content published in IJGCR. Science advances through dialogue, debate, and the rigorous examination of evidence. We welcome letters to the editor, commentaries, and responses that extend the discussion initiated by published articles.

Collaboration with the International GI Cancers Conference (IGICC)

IJGCR is intimately connected with the IGICC, which has served as the premier annual gathering for GI oncology professionals since 2010. The journal will serve as an official publication venue for selected presentations and research from IGICC, and we anticipate that many of the most significant advances discussed at IGICC will find their way into the pages of IJGCR. This synergy between conference and journal will create a dynamic ecosystem for scientific exchange and knowledge dissemination.

Challenges and Opportunities

The field of GI oncology faces significant challenges. GI cancers remain among the most lethal malignancies, with 5-year survival rates for many subtypes remaining disappointingly low. Geographic disparities in cancer incidence, access to treatment, and research capacity remain profound. Many patients with GI cancers present at advanced stages, limiting the potential for curative treatment. Drug resistance and treatment-related toxicities continue to limit the efficacy of our therapeutic arsenal.

Yet these challenges also present extraordinary opportunities. The rapid pace of scientific discovery-in immunotherapy, targeted therapy, precision medicine, and surgical innovation-offers genuine hope for improved outcomes. Emerging technologies such as artificial intelligence, liquid biopsy, and advanced imaging promise to revolutionize early detection and treatment planning. The increasing recognition of the importance of multidisciplinary care, patient-centered outcomes, and health equity creates opportunities to optimize care delivery and improve quality of life for patients with GI cancers.

A Call to Action

As we launch IJGCR, I extend a heartfelt invitation to the global GI oncology community. Whether you are a basic scientist investigating the molecular biology of GI cancers, a clinical researcher conducting therapeutic trials, a practicing oncologist seeking to advance patient care, or a patient advocate working to improve outcomes for those affected by these diseases, IJGCR is your journal. This is a platform for your work, your ideas, and your voice.

I am confident that IJGCR will become an indispensable resource for the GI oncology community-a journal where the most important research is published, where rigorous science meets clinical relevance, and where the collective wisdom of the global community is brought to bear on the challenge of conquering GI cancers.

Acknowledgments

The launch of IJGCR would not have been possible without the dedication and support of many individuals and institutions. I wish to express my gratitude to the members of the editorial board, who have committed their time and expertise to ensuring the highest standards of scientific excellence. I am deeply grateful to Galenos Publishing House, whose commitment to academic publishing and whose innovative publishing platforms have made this journal possible. I also wish to acknowledge the countless researchers, clinicians, and patients whose work and experiences have inspired the creation of this journal.

Looking Forward

As we embark on this exciting journey, I am filled with optimism about the future of GI oncology. The advances we have witnessed in recent years, and those yet to come, offer genuine hope that we can improve outcomes for patients with these devastating diseases. IJGCR will serve as a beacon, illuminating the path forward and connecting the global community of researchers and clinicians who are dedicated to this mission.

I invite you to visit the journal website at https://gicancerjournal.com/ to learn more about our editorial policies, submission guidelines, and the full editorial board. I encourage you to submit your work, to serve as a peer-reviewer, and to engage as a reader and contributor to this exciting new venture in scientific publishing.

EDITORIAL

Together, we will advance the science and practice of GI oncology and ultimately, improve the lives of patients affected by these diseases.

With warm regards and best wishes for the success of IJGCR,

Editor-in-Chief: Prof., MD. Şuayib Yalçın

Hacettepe University Cancer Institute, Ankara, Türkiye

About the Editor-in-Chief

Prof., MD. Şuayib Yalçın is the Director of the Hacettepe University Cancer Institute and a leading figure in GI oncology in Türkiye and internationally. He has served as the Chairman of the IGICC and is recognized for his contributions to advancing multidisciplinary cancer care and research. Prof., Yalçın has published extensively in peer-reviewed journals and is a frequent speaker at international conferences on topics related to GI malignancies and precision oncology.

16th International Gastrointestinal Cancers Conference (IGICC 2026): Invitation, General Information and Conference Program

Invitation to 16th IGICC 2026 in Istanbul

Dear Colleagues,

On behalf of the Organizing Committee, I am pleased to invite you to the 16th IGICC 2026, to be held between December 17-20, 2026. The meeting will be held in a hybrid format, with online sessions and in-person sessions at The Marmara Taksim Hotel in İstanbul, Türkiye. However, in person sessions can be viewed live online if registered to the conference. You can get detailed information at the conference website; **www.igicc.org**

Building on the experience gained through the previous fifteen meetings, IGICC 2026 will once again provide a great forum for education, scientific exchange, and discussion of current developments in gastrointestinal cancer management. The hybrid format will make the scientific content accessible to a wider international audience while preserving the direct interaction and multidisciplinary exchange offered by an in-person meeting.

The scientific program covers the main areas of gastrointestinal oncology, including gastrointestinal, hepatobiliary, and pancreatic cancers; neuroendocrine tumors (NETs); gastrointestinal stromal tumors (GISTs); gastrointestinal lymphomas; and supportive/palliative care. The program has been developed for medical oncologists, radiation oncologists, surgeons, pathologists, gastroenterologists, nuclear medicine specialists, and other professionals involved in the care of patients with gastrointestinal cancers.

The program will include keynote lectures, educational sessions, multidisciplinary tumor board discussions, case-based presentations, and oral and poster presentations. Both online and in-person participants will be able to follow current scientific discussions, exchange experience with colleagues, and develop new professional and research connections.

We cordially invite you to join us by attending the conference either online or in person and to contribute to the scientific program by submitting your scientific work for consideration as an oral or poster presentation.

We are looking forward to welcoming you to IGICC 2026 in December 17-20 in Istanbul, where continents meet.

Sincerely,

Prof. MD. Şuayib Yalçın Chair, IGICC 2026 Hacettepe University Cancer Institute Ankara, Türkiye

16th IGICC 2026:

Introduction and Historical Background

Since its first meeting in 2011, the IGICC has grown into an established annual meeting for professionals working in gastrointestinal oncology. Over sixteen years, it has developed from a regional initiative into an international conference, bringing together thousands of participants from more than 50 countries across six continents. Throughout this period, IGICC has focused on sharing most current research and information, discussing its application in clinical practice, and supporting international collaboration.

Legacy of Previous Conferences

IGICC's development is reflected not only in increasing attendance but also in the way discussions held at the meeting have contributed to clinical practice and research priorities. Previous conferences have also supported consensus-building, encouraged international research partnerships, and provided a platform for the discussion of new treatment approaches.

IGICC 2011-2015: Foundational Years

The first meetings established IGICC as a multidisciplinary forum in gastrointestinal oncology. During this period, specialists from different fields came together to discuss clinical practice and emerging evidence. The multidisciplinary model-bringing together medical oncology, surgical oncology, radiation oncology, and supportive care-became a defining feature of the conference from the outset.

IGICC 2016-2020: The Era of Precision Oncology

As molecular diagnostics and genomic profiling became more widely available, the program increasingly addressed how molecular findings could be incorporated into clinical decision-making. Targeted therapies for specific molecular subtypes and the clinical relevance of emerging biomarkers became important areas of discussion.

IGICC 2021-2025: Immunotherapy and Personalized Care

The most recent meetings reflected the growing role of immunotherapy in gastrointestinal oncology. IGICC 2021 included presentations on checkpoint inhibitor combinations in advanced gastric cancer, while IGICC 2023 addressed neoadjuvant immunotherapy in colorectal cancer. During the same period, the program gave greater attention to patient-centered care, including palliative medicine, nutritional support, and psycho-oncology. The value of IGICC extends beyond the meeting itself. In the post-conference survey conducted after IGICC 2024, 87% of respondents reported that they had introduced new clinical strategies based on conference presentations. In addition, 64% stated that they

had started new research collaborations with colleagues they met at the conference, and 92% rated the multidisciplinary case discussions as “highly valuable” or “essential”.

Current Landscape of Gastrointestinal Cancers

Gastrointestinal cancers remain a major cause of illness and death worldwide. According to the Global Cancer Observatory, they account for approximately one in four cancer cases and one in three cancer-related deaths globally. These figures underline the continuing need to share evidence, strengthen international collaboration, and improve the transfer of current knowledge into daily practice. These priorities remain central to IGICC 2026.

Conference Objectives

IGICC 2026 aims to:
• Present clinically relevant updates across gastrointestinal oncology;
• Support multidisciplinary discussion of complex and controversial cases;
• Encourage the exchange of experience between national and international participants;
• Provide a platform for oral and poster presentations; and
• Strengthen future clinical and research collaborations.

IGICC 2026 at a Glance

December 17-20, 2026 | Hybrid format | Online and in-person sessions | The Marmara Taksim Hotel, Istanbul | Four-day multidisciplinary scientific program | Oral and poster presentations

IGICC 2026 Conference Program Overview

IGICC 2026 will offer a four-day scientific program combining online and in-person sessions. This format is intended to provide flexibility for participants while maintaining direct scientific discussion and interaction.

Conference Format and Participation Options

Virtual sessions (online): Thursday, December 17, 2026, 08:00-17:55 (GMT+3) participants can attend educational sessions remotely, ensuring global accessibility.

On-site Sessions (In-person): Thursday-Sunday, December 17-20, 2026, at The Marmara Taksim Hotel, İstanbul In-person participants benefit from direct interaction with faculty, networking opportunities, and multidisciplinary case discussions. But the sessions can be followed live online if registered, and later can be viewed at IGICC.TV at the conference website IGICC.org.

Detailed Program Schedule

Thursday, December 17, 2026-VIRTUAL SESSIONS (Online)

08:00-11:15: Update on Immunotherapy as a Standard of Care for Gastrointestinal Cancers

This three-part session reviews the transformative role of immunotherapy across the gastrointestinal cancer spectrum:

Part I (08:00-09:15): Foundational principles of immunotherapy in GI oncology, including basics and rationale for immune-oncology treatment, the impact of glucocorticoid use on immunotherapy efficacy, and management strategies for immune-related adverse events.

Part II (09:15-10:25): Disease-specific immunotherapy applications including esophageal cancer, gastroesophageal and gastric adenocarcinoma, hepatocellular cancer, and biliary tract cancers.

Part III (10:25-11:20): Additional GI malignancies including pancreatic cancer, colorectal cancer, and anal cancer, with comprehensive discussion of immunotherapy sequencing and combination strategies.

11:20-12:15: Anti-VEGF and Anti-EGFR Therapies for Metastatic Colon Cancers: Basic Principles

This session explores the fundamental mechanisms and clinical applications of vascular endothelial growth factor (VEGF) inhibitors and epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer management, including patient selection criteria and combination strategies.

12:15-13:00: Antibody-drug Conjugates and CAR-T Cell Treatment in GI Oncology: Where Do We Stand

Emerging therapeutic modalities including antibody-drug conjugates (ADCs) and chimeric antigen receptor T-cell (CAR-T) therapies are discussed, with emphasis on current clinical evidence and future directions in gastrointestinal oncology.

13:00-16:15: Update on the Supportive and Palliative Care in GI Cancer Patients (Parts I & II)

This extended session addresses the critical supportive care needs of GI cancer patients:

Part I: Management of chemotherapy-induced neutropenia, chemotherapy-induced nausea and emesis (CINV), and survivorship issues including functional recovery, fertility, and sexual health.

Part II: Management of adverse events related to emerging targeted therapies (Claudin 18.2, ADCs, HER2, FGFR inhibitors), cancer pain management, vaccination strategies, micronutrient deficiencies (magnesium), cancer-associated fatigue and anemia, bone health in GI cancer patients, frailty assessment in older patients, and integrative oncology approaches.

16:15-16:55: Common Clinical Challenges in Daily GI Oncology Practice

Practical clinical scenarios including polypharmacy management, anticoagulation strategies, and optimal timing of surgery after neoadjuvant therapy.

16:55-17:55: Rare Tumors

Discussion of uncommon gastrointestinal malignancies including small bowel adenocarcinoma, appendiceal neoplasms and pseudomyxoma peritonei, hemangioendothelioma, and pancreatic pseudopapillary tumors.

Thursday, December 17, 2026 - ON-SITE SESSIONS (In-person)

13:00-13:45: Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

This session covers WHO classification updates, modern imaging and theranostic approaches, the evolving role of surgery, and treatment sequencing in advanced GEP-NETs with emphasis on precision oncology and molecular profiling (NETest).

13:00-13:45: Artificial Intelligence in GI Oncology

Parallel session exploring AI applications in medical imaging, digital pathology, clinical decision support systems, and their integration into gastrointestinal cancer management.

13:45-14:35: Peritoneal Surface Malignancies in GI Cancers

Organized in collaboration with the Turkish Peritoneal Surface Oncology Society (PYOD), this session addresses the biology of peritoneal metastases, patient selection for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), integration of systemic therapy with regional treatments, and pressurized intraperitoneal aerosol chemotherapy (PIPAC) techniques.

13:45-14:50: Rare Tumors (On-site)

Discussion of desmoid tumors, adrenocortical carcinoma, fibrolamellar hepatocellular carcinoma, and malignant peritoneal mesothelioma.

16:05-16:30: Coffee Break and Networking

16:30-16:45: Anal Cancers: Comprehensive Approach

HPV vaccination strategies, screening and early detection methods, neoadjuvant treatment approaches, and first and second-line systemic therapy for anal cancers.

17:00-18:10: Current Concepts in GIST Management

Precision pathology and molecular classification, the evolving role of surgery (neoadjuvant therapy, organ preservation, metastasectomy), adjuvant therapy patient selection, and treatment sequencing in advanced GIST based on molecular alterations.

Friday, December 18, 2026 - ON-SITE SESSIONS

08:00-09:00: Current Management of Esophageal Cancer

Coverage of localized esophageal squamous cell carcinoma, perioperative treatment of esophageal adenocarcinoma (chemotherapy vs. chemoradiotherapy vs. immunotherapy), advanced disease management in the immunotherapy era, and oligometastatic disease treatment strategies.

09:00-10:00: Advances in the Treatment of Gastroesophageal and Gastric Adenocarcinoma

Clinical characteristics of molecular subtypes (HER2, CLDN18.2, FGFR2b, MSI, PD-L1, EBV, emerging biomarkers), optimization of perioperative treatment, and first-line treatment selection for advanced disease in the precision oncology era.

10:00-10:40: Keynote Lecture: Standard and Emerging Systemic Treatment Options for Advanced GEJ and Gastric Adenocarcinoma

10:30-11:00: Industrial Symposium

11:00-11:20: Coffee Break and Networking

11:20-12:50: Early Detection, Screening and Surveillance in GI Cancers

Risk-adapted screening strategies, blood-based screening and emerging molecular technologies, upper GI cancer screening standards, colorectal cancer screening integration, and circulating tumor DNA (ctDNA) for minimal residual disease detection and surveillance.

Moderated Session (75 minutes): Discussion of gastroesophageal junction cancer management including epidemiology and diagnosis, multidisciplinary neoadjuvant care (FLOT, CROSS protocols), surgical strategy based on Siewert classification, lymphadenectomy controversies, minimally invasive and robotic techniques, and complication management with adjuvant therapy.

12:50-13:30: Lunch

13:30-14:00: Keynote Lecture: The New Era of RAS-Targeted Therapy

Review of RAS-targeted therapy evolution including spesific KRAS G12C, KRAS G12D/G12V, pan-RAS inhibitors, RAS(ON) inhibitors, resistance mechanisms, and future directions.

14:30-15:00: Industrial Symposium

15:00-16:15: Current Management of Pancreatic Cancer

Precision oncology in pancreatic cancer with biomarker-guided treatment, perioperative strategies for resectable and borderline resectable disease, evolving role of radiotherapy, and advanced pancreatic cancer management.

16:15-16:35: Coffee Break and Networking

16:35-17:35: Tissue-agnostic Pathways as Therapeutic Targets in GI Cancers

DNA damage response and repair (DDR) alterations including HRD and PARP inhibitors, gene fusion-driven cancers (RET, NTRK, NRG1/2, ALK, ROS1), and hypermutated tumors with emerging molecular targets.

16:35-17:35: Nutrition, Exercise & Cancer Cachexia Masterclass

Cancer cachexia recognition and assessment, nutrition and exercise oncology from prehabilitation to survivorship, multimodal management strategies, and case-based practical management.

17:35-18:20: Optimizing Preventive Care in GI Tumors

DPYD testing strategies, hepatitis prophylaxis, and prophylactic antibiotic use in GI cancer patients receiving systemic treatment.

Friday, December 18, 2026 - Parallel Session

11:30-13:00: Psycho-oncology & Palliative Care Integration

Early integration of palliative care in GI cancers, management of anxiety and depression, communication of difficult news, caregiver burden assessment, and supportive care strategies.

14:50-16:25: Therapeutic Role of Interventional Radiology in GI Cancers

Organized by the Turkish Interventional Oncology Society, this session covers ablative techniques (RFA, MWA, cryoablation), transarterial techniques (TACE, TARE, HAIC), portal vein embolization, interventional radiology in pain management, and vertebroplasty.

Saturday, December 19, 2026 - ON-SITE SESSIONS

08:00-09:25: Current Management of Localized Colon Cancer

Endoscopic management of early colorectal cancer, neoadjuvant treatment strategies for MSS vs. MSI-H disease, personalized adjuvant therapy, ctDNA-guided treatment, and lifestyle and metabolic interventions for recurrence prevention.

09:25-10:30: Precision Systemic Treatment for Metastatic Colorectal Cancer - Part I

Biomarker-driven first-line treatment selection, KRAS targeting in mCRC, BRAF V600E-mutant mCRC management, HER2-positive mCRC treatment, and treatment intensification strategies.

10:40-12:10: Precision Systemic Treatment for Metastatic Colorectal Cancer - Part II

Treatment sequencing and integration of local therapies, maintenance therapy optimization, second-line biomarker-guided approaches, later-line treatment strategies, oligometastatic disease management, radiotherapy and ablative therapy integration, and liver-directed therapies (TARE, HAIC).

12:10-13:15: Special Populations and Emerging Challenges in Colorectal Cancer

Early-onset colorectal cancer epidemiology and biology, treatment optimization in older adults, hereditary colorectal cancer and germline testing, gender differences in colorectal cancer, and colorectal cancer epidemiology and screening needs in Türkiye.

13:30-14:15: Lunch

14:15-14:55: Liver Transplantation in Colorectal Liver Metastases

Evidence from SECA and TRANSMET trials, patient selection criteria, multidisciplinary decision-making, and future perspectives.

14:55-15:55: Industrial Symposia

15:55-16:20: Coffee Break and Networking

16:20-17:35: Current Management of Localized Rectal Cancer

Total neoadjuvant therapy (TNT) strategies, TNT optimization (induction vs. consolidation chemotherapy), neoadjuvant immunotherapy for dMMR/MSI-H disease, organ preservation approaches (watch-and-wait, local excision), and personalized treatment selection.

17:35-18:20: Keynote Lecture: Building Regional Oncology Networks in Central & Eastern Europe

Regional collaboration, clinical trial access, and ambassadorship in advancing gastrointestinal oncology.

Sunday, December 20, 2026 - ON-SITE SESSIONS

08:00-09:15: Prevention, Early Detection and Diagnosis of Hepatocellular Carcinoma (Part I)

Prevention strategies (viral hepatitis, metabolic-associated fatty liver disease), risk stratification and surveillance protocols, imaging diagnosis (LI-RADS, MRI), HCC pathology and biomarkers, and staging systems (BCLC, TNM, Child-Pugh, ALBI).

09:15-11:00: Treatment and Multidisciplinary Management of Hepatocellular Carcinoma (Part II)

Hepatic resection techniques, liver transplantation indications, intermediate-stage HCC management, TACE and radioembolization (Y-90) strategies, radiation therapy approaches (SBRT, external beam radiotherapy), first-line therapy selection, and treatment after progression.

11:00-13:00: Current Multidisciplinary Management of Biliary Tract Cancers

Precision pathology in biliary cancers, surgical management of intrahepatic, perihilar, and distal cholangiocarcinoma, targeted therapies for FGFR2 fusions and IDH1 mutations, and systemic treatment strategies.

Target Audience and Participant Profile

The IGICC 2026 program is intended for professionals from the following specialties:

Specialty	Role and expectations at the conference
Medical oncologists	Gain current knowledge on systemic therapy algorithms, immunotherapy combinations, biomarker-guided treatment selection, and emerging drug approvals.
Radiation oncologists	Discuss advanced radiotherapy techniques (SBRT, proton therapy), neoadjuvant/adjuvant chemoradiation protocols, and organ-preserving approaches.
Surgical oncologists	Share experience on minimally invasive techniques, complex resection margins, metastasectomy indications, and perioperative complication management.
Gastroenterologists	Receive updates on early detection methods, advanced endoscopic resection techniques, and palliative endoscopic interventions.
Pathologists and geneticists	Participate in discussions on molecular profiling, biomarker analysis, precision pathology, and new WHO classifications.
Interventional radiologists	Learn about advanced ablative and transarterial techniques, theranostic approaches, and pain management strategies.
Nuclear medicine specialists	Explore advanced imaging techniques (PET/CT, PET/MRI) and theranostic applications (PRRT, radioembolization).

Registration, Accommodation, and Logistical Information

Registration Options and Fees

IGICC 2026 offers separate registration options for online and in-person participation. A 20% VAT will be added to all registration fees.

Registration type	Until August 7, 2026	August 8 - September 11, 2026	On or After September 11, 2026
Virtual registration (online only)	80 €	100 €	150 €
Physical registration (in-person)	50,000 TL	55,000 TL	60,000 TL

Note: No cancellations of conference registrations will be accepted after August 7, 2026. However, participant name substitutions will be permitted upon written notification.

Accommodation Information

Accommodation for in-person participants is available at The Marmara Taksim Hotel. The rates below are for a three-night package, with check-in on December 17 and check-out on December 20, on a bed-and-breakfast basis. A 10% VAT will be added to the accommodation fees.

Room type	Until August 7, 2026	August 8 - September 11, 2026	On or after September 11, 2026
Single room (SNG)	1,450 EURO	1,550 EURO	1,600 EURO
Double room (per person)	900 EURO	1,000 EURO	1,100 EURO

Transfer Services and Banking Information

Transfer Services: Round-trip group shuttle transfer between İstanbul Airport and the hotel is available at 200 EURO per person. Transfers will be organized for participants who have previously submitted their flight details to UNICON MICE.

Payment Information: Registration and accommodation requests become valid only after submitting your request to igicc@uniconmice.com, receiving budget approval, and sending the bank receipt evidencing payment to UNICON MICE. Payments should be made to the following VAKIFBANK accounts:

HESAP ADI: Unicon Mice Kongre Turizm Organizasyon Hiz. Tic.Ltd.Şti.

BANKA ADI: GARANTİ BANKASI

BANKA SWİFT KODU: TGBATRISXXX

ŞUBE ADI: ULUS ŞUBE - 395

TL IBAN: TR38 0006 2000 3950 0006 2947 20

EURO IBAN: TR03 0006 2000 3950 0009 0565 52

USD IBAN: TR14 0006 2000 3950 0009 0551 90

Conclusion

The 16th International Gastrointestinal Cancers Conference will provide an opportunity to review current developments across the rapidly changing field of gastrointestinal oncology. Through four days of online and in-person sessions, the meeting will combine scientific updates, practical discussion, and multidisciplinary exchange for professionals involved in the management of gastrointestinal cancers.

Building on the experience of the previous fifteen conferences, IGICC 2026 will continue to connect clinical practice with current research. Participants attending online or in person will be able to hear from experienced national and international faculty, discuss recent evidence, and meet colleagues working in the same field.

We look forward to welcoming you to IGICC 2026 and to your contribution to the scientific discussions in Istanbul and online.